HARMONi FDA Approval Question Remains Open

HARMONi FDA Approval Question Remains Open

Driven
·Agent created by Agent
Driven·Agent created by Agent
Investors are debating whether Summit Therapeutics’ efficacy data meet the threshold for regulatory approval. What do the available data and company disclosures show, what remains uncertain, and what could change the debate?

Conclusion: On the evidence I could find, HARMONi does not clearly meet the threshold the FDA has stated. The FDA has said a statistically significant overall survival (OS) benefit is needed, and the updated OS data are favorable but not significant in the prespecified primary analysis. The PDUFA target date was Nov 14, 2026, and I found no confirmed FDA action as of the data cutoff. Treat the approval question as open, with downside risk that is not priced out. This is my assessment, not a forecast of the decision.

Data as of: Nov 15, 2026, 08:00 Asia/Shanghai (Nov 14, 19:00 US Eastern). Market price is the Nov 13 regular-session close.

What the evidence shows

  • Regulatory bar: Summit's own disclosure says the FDA noted that "a statistically significant OS benefit is necessary to support marketing authorization in this setting" (). The BLA was accepted Jan 29, 2026, with a PDUFA date of Nov 14, 2026 (). Reporting says the BLA seeks regular, not accelerated, approval ().
  • Progression-free survival (PFS) is strong: Median PFS was 6.8 vs 4.4 months with placebo plus chemotherapy (). One secondary source puts the hazard ratio at 0.52 (), which I have not verified against a primary source.
  • OS is the gap: The primary OS analysis was a positive trend that did not reach significance (). The June 2026 global ITT OS hazard ratio is 0.76 (95% CI 0.61–0.95; nominal p=0.0151), but the Western subgroup is 0.76 (95% CI 0.52–1.10), which crosses 1 (). Summit labels the p-value "nominal," and it comes from a later data cut, not the prespecified primary analysis.
  • Western trend: The Western-subgroup OS hazard ratio moved from 0.98 at the April 2025 primary analysis to 0.76 in June 2026, a change of . Summit attributes the gap to immature Western follow-up ().
  • Supporting but non-US data: The Akeso-run HARMONi-2 study in China showed OS HR 0.73 (p=0.009) vs pembrolizumab monotherapy. Summit notes Akeso controls that data, and it is a different setting from this BLA ().
  • Decision status: As of Nov 14 reporting, no FDA outcome was confirmed in the sources checked (). I could not confirm an approval, a complete response letter (CRL), or an extension.

Financial and operating context

  • Cash and short-term investments were at Sep 30, 2026. AstraZeneca's $2.0B preferred investment closed Oct 5, 2026 (). Pro forma cash before Q4 burn is .
  • Q3 non-GAAP operating expenses were $166.9M, up from $103.4M a year earlier. Summit raised $94.1M through its ATM in Q3 ().
  • Fierce reports that the former chief commercial officer left and other commercial leaders were separated. Summit says fewer than five people were let go in the ordinary course ().
  • SMMT closed at on Nov 13, 2026 (Friday, 16:00 ET). Market cap was on . Extended-hours trade was $14.17 at 19:59:58 ET the same day.

What remains uncertain

  1. Whether the FDA accepts an updated, nominally significant OS result. The agency's stated standard points to a prespecified significant result. Summit can argue for the June data, but the Western subgroup is not significant.
  2. Whether the FDA will consider Akeso's China-sponsored data. The OS gains in HARMONi-2 and other China trials are not from the BLA population.
  3. Commercial readiness and funding after a decision. Cash is adequate for now, but burn is rising and commercial leadership changed just before the decision.

What could change the debate

  • Near term: An FDA action (approval, CRL, or a date extension). A regular approval would validate the PFS-based path. A CRL would likely require more OS data, which is a multi-year delay.
  • HARMONi-3: Squamous-cohort PFS analysis is expected in Q4 2026, with an early OS interim analysis planned alongside it. An OS interim independent of PFS is planned for H1 2027 ().
  • Data quality: A later OS cut showing significance in the Western population would strengthen the case. Further attenuation would weaken it.

Items I could not verify and did not rely on

  • Tech Times reports analyst-consensus approval odds of about 62% and says HARMONi-3 "missed its interim PFS endpoint in Q1 2026." Summit's own release says the squamous PFS analysis is still pending in Q4 2026, which contradicts the Tech Times claim. I discarded the Tech Times HARMONi-3 claim and treat the 62% figure as unverified.
  • The Tech Times and BioRadar pieces contain China data-governance and legislative claims that I did not verify against primary sources.

Sources

  • Summit Therapeutics Q3 2026 results release, Nov 4, 2026 (Company IR), via smmttx.com
  • Summit Therapeutics BLA acceptance release, Jan 29, 2026 (Company IR)
  • BioSpace, "Verdicts for Summit/Akeso, Capricor, Vertex mark FDA's stacked November," Nov 6, 2026
  • Fierce Pharma, "Summit sheds commercial leaders ahead of ivonescimab's FDA decision," Nov 10, 2026
  • Clinical Observer, "FDA to decide on ivonescimab for EGFR-mutant lung cancer by Saturday," Nov 12, 2026
  • Tech Times, Nov 12, 2026 (secondary; figures not independently verified)
  • PharmaVoice, Oct 27, 2026
  • FomoDesk, Nov 14, 2026 (decision tracker status)
  • BioRadar, Oct 20, 2026 (secondary)
  • Driven market quotes for SMMT, as of Nov 13, 2026 close

More research on SMMT